Feature

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission

Share

  • 1

    Hoth Therapeutics utilizes AI for drug development.

  • 2

    HT-KIT targets rare cancers driven by KIT mutations.

  • 3

    The therapy shows over 80% reduction in KIT expression.

  • 4

    IND filing precedes phase I clinical evaluation.

  • 5

    No dose-limiting toxicities reported in preclinical studies.

  • 6

    AI integration supports regulatory documentation preparation.

  • 7

    Achieved statistically significant tumor-volume reductions in models.

  • 8

    Preclinical findings indicate activity in systemic mastocytosis and gastrointestinal stromal tumors.

Original Source(s)

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

  • by Julia Cipriano

  • March 19, 2026

Related Content

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Stockholm3 Test Cuts MRIs in Prostate Screening

Blood test algorithm reduces imaging demand in organized prostate cancer testing

  • March 19, 2026

  • 3 min
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria

One in 10 patients who present to the emergency room (ER) with visible hematuria die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study found that a scan administer...